INFU Stock Analysis: Buy, Sell, or Hold?
INFU - InfuSystem Holdings, Inc.
$10.05
1.00 (11.05%)
▲
5d:
+6.69%
30d:
+8.65%
90d:
+3.61%
BUY
MODERATE Confidence
Analysis Updated: Jun 26, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Get Alerted When INFU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: INFU shows positive signals but monitor for confirmation. Market pricing in 1.1% decline. Moderate conviction.
💡 BUY OPPORTUNITY: INFU shows positive signals but monitor for confirmation. Market pricing in 1.1% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$20.27
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$12.59
20.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 19.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: INFU is currently trading at $10.05, which is considered extended relative to its 30-day fair value range of $8.82 to $9.57. The stock's valuation (Forward PE: 18.4) is in line with its historical norms (19.1). Remarkably, the market is currently pricing in an annual earnings decline of 1.1% over the next few years. This pessimistic expectation contrasts with the company's recent 123.9% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, INFU is in a uptrend. The price is approaching resistance at $9.62. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 11.0% recently.
Market Sentiment: INFU has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $14.88 (+48.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, INFU is in a uptrend. The price is approaching resistance at $9.62. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 11.0% recently.
Market Sentiment: INFU has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $14.88 (+48.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$8.82 -
$9.57
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range (+5.0% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+11.0%)
- BULLISH: Trading 48.0% below Wall St target ($14.88)
Trading Range Analysis
30-Day Trading Range
$8.82 -
$9.57
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$8.75
Resistance Level
$9.63
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
18.44
Wall Street Target
$14.88
(+48.0%)
Revenue Growth (YoY)
-3.0%
Earnings Growth (YoY)
123.9%
Profit Margin
5.5%
Valuation Discount vs History
-1.1% cheaper
PE vs Historical
18.4 vs 19.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.1%
(market-implied from PE analysis)
1-Year Target
$9.94
(-1%)
2-Year Target
$9.83
(-2%)
3-Year Target
$9.72
(-3%)
3-Yr Target (if PE normalizes)
(PE: 18→19)
$10.07
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 28.2%)
$25.03
(+149%)
Base:
(SPY PE: 18.4, Growth: 28.2%)
$21.19
(+111%)
Bear:
(PE: 15.7, Growth: 28.2%)
$18.01
(+79%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (24x PE), but valuation improves significantly next year (18x PE) as earnings recover.
Trailing PE: 24.46 | Current EPS (TTM): $0.37
Bull Case
$14.66
(+46%)
Analyst growth 47.3%, PE expands to 26.9
Base Case
$13.33
(+33%)
Market implied 47.3%, PE stable at 24.5
Bear Case
$6.15
(-39%)
Severe decline -20.0%, PE contracts to 20.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 18.4 to 19.1
Stabilization Target:
$10.41
(+3.6%)
PE Expansion Potential:
+3.6%
Share & Embed Analysis
Last updated: June 28, 2026 1:04 PM ET
Data refreshes hourly during market hours. Next update: 2:04 PM
Data refreshes hourly during market hours. Next update: 2:04 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INFU showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Barry G Steele
BUY
2064 shares
2026-03-02
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$75 | 66 BUY |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 65 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 55 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$117 | 68 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$240 | 65 BUY |
